News from soterix medical inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 26, 2021, 14:00 ET Soterix Medical study to address post-COVID neurological and psychiatric symptoms using at-home neuromodulation and monitoring

Soterix Medical Inc. (SMI), the global leader in non-invasive stimulation and synergistic brain imaging technologies, announces a new clinical trial...

Dec 24, 2020, 15:13 ET Soterix Medical Announces Expanded Clinical Trials for Alzheimer's disease and Mild Cognitive Impairment

Soterix Medical Inc. , the global leader in non-invasive stimulation and synergistic brain imaging technologies, is pleased to report expanded...

Jul 07, 2020, 15:53 ET FDA Grants Soterix Medical IDE Approval for Home-based tDCS-LTE Trial for Depression

Soterix Medical Inc. announces it has received FDA Investigational Device Exception (IDE) to launch a trial of transcranial Direct Current...

May 15, 2019, 10:40 ET Soterix Medical Announces launch of electro-detox Treatment for Opioid Withdrawal

Soterix Medical Inc. announced today the launch of its U.S. Food and Drug Administration (FDA) 510k cleared electro-detox™ treatment to reduce opiate ...

Mar 31, 2014, 08:15 ET Soterix Medical Awarded Another Patent for High-Definition transcranial Direct Current Stimulation Platform

Soterix Medical Inc. announces receipt of allowance of claims from the U.S. Patent Office for an application covering their system and method of...

Dec 02, 2013, 09:43 ET Soterix Medical Inc., Rogue Resolutions Ltd., and neuroConn GmbH announce MOBILE neuromodulation platform at NYCneuromodulation 2013 conference

At the NYCneuromodulation 2013 conference, Soterix Medical Inc. , Rogue Resolutions Ltd, and neuroConn GmbH announced the revolutionary MOBILE...

Oct 29, 2013, 12:37 ET Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)

Soterix Medical Inc. announces today a Phase 3 trial for Major Depressive Disorder (MDD) that will compare Soterix Medical's Transcranial Direct...